Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages
Withsix marketed drugs, ADCs are presently recognized as a potent class of targetedanticancer therapies, with the potential to be used to treat a variety of otherdisease indications. The success of such products can be attributed to theirability to effectively identify and eliminate disease associated cells /pathogens, with substantially lower risk of treatment related side effects.
To order this 600+page report, which features 190+ figures and 280+ tables, please visit this link
The USD 15 billion (by 2030) financial opportunitywithin this market has been analyzed across the following segments:
§ Type of Payload
§ MMAE
§ DM4
§ Camptothecin
§ DM1
§ MMAF
§ Others
§ Type of Linker
§ VC
§ Sulfo-SPDB
§ SMCC
§ VA
§ Hydrazone
§ Others
§ Target Indication
§ Breast cancer
§ Lymphoma
§ Leukemia
§ Urothelial cancer
§ Lung cancer
§ Ovarian cancer
§ Others
§ Target Antigen
§ CD30
§ HER2
§ CD22
§ CD33
§ Others
§ Technology Providers
§ Seattle Genetics
§ ImmunoGen
§ StemCentRx
§ Immunomedics
§ Others
§ Key Geographical Regions
§ North America
§ Europe
§ Asia Pacific
The Antibody Drug Conjugates Market (5th Edition), 2019-2030 report features thefollowing companies, which we identified to be key players in this domain:
§ Bristol Myers Squibb
§ GlaxoSmithKline
§ Incyte
§ Novartis
§ Trillium Therapeutics
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
1. Market Overview
5. Company and Drug Profiles
6. Key Therapeutic Areas
7. Key Opinion Leaders
8. Target Competitiveness Analysis
9. Partnerships and Collaborations
10. Funding and Investment Analysis
11. Patent Analysis
12. Academic Grants
13. Key Commercialization Strategies
14. Promotional Analysis
15. Combination Therapies
16. Novel Conjugation Technology Platforms
17. Assessment of Non-Clinical Data, First in Human Dosing
18. Cost Price Analysis
19. Case Study: Contract Manufacturing of ADC
20. Case Study: Companion Diagnostics for ADC Therapeutic
21. Market Forecast and Opportunity Analysis
22. Swot Analysis
23. Conclusion
24. Executive Insights
25. Appendix 1: Tabulated Data
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
